Endoscopic therapy of sporadic non-ampullary duodenal adenomas, single centre retrospective analysis. (1st February 2023)

• Record Type: Journal Article
• Authors: Udd, Marianne; Lindström, Outi; Tenca, Andrea; Rainio, Mia; Kylänpää, Leena
• Is Part Of: Scandinavian journal of gastroenterology. Volume 58:Number 2(2023)
• Page Start: 208
• Page End: 215
• Publication Date: 2023-02-01
• Subjects: Duodenal adenoma -- endoscopic therapy -- complication -- mortality -- Gastroduodenal-clinical; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2022.2114810
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Introduction: Although sporadic non-ampullary duodenal adenomas (SNADA) are rare, with the risk of progression to cancer, they deserve therapy. Endoscopic therapy of SNADA is effective, but with the increased risk of complications, endotherapy should be performed in high-volume units. The results of endotherapy of SNADA in our unit are presented. Patients and methods: A total of 97 patients with SNADA had endoscopic resection in 2005–2021 and control endoscopies between 3 and 24 months. Snare polypectomy, endoscopic mucosal resection (EMR), endoscopic band ligation (EBL) and endoloop were used (en bloc 37% and piecemeal 63%). In cases of residual/recurrent adenomas, endotherapy was repeated. Results: The median size of the adenoma was 12 (5–60) mm and most polyps were sessile (25%) or flat (65%). Primary endotherapy eradicated adenomas in 57 (59%) cases. Residual and recurrence rates were 24% ( n = 23) and 17% ( n = 16) with successful endotherapy in 16 (70%) and 13 (81%) patients. Endotherapy was successful in 86 (89%) patients after a median (range) follow-up of 23 (1–166) months. Four out of 11 patients with failed endotherapy had surgery; seven patients were not fit for surgery. There were no disease-specific deaths or carcinoma. Eleven patients (11%) suffered from complications: perforation requiring surgery ( n = 1), sepsis ( n = 1), postprocedure bleeding ( n = 7), cardiac arrest ( n = 1) and coronary infarct ( n = 1). The thirty-day mortality was zero. Colonoscopy was performed on 67 (69%) patients with neoplastic lesions in 33% patients during follow-up. Conclusions: Endotherapy of SNADA is effective and safe. Repeat endotherapy in residual and recurrent adenomas is successful. Careful patient selection is mandatory. Abbreviations: ASA: American Society of Anesthesiologist classification; BMI: body mass index; CT: computed tomography; EBL: endoscopic band ligation; EMR: endoscopic mucosal resection; ESD: endoscopic submucosal dissection; ET: endotherapy; FAP: familial adenomatous polyposis; F: female; LST: laterally spreading tumours; M: male; SD: standard deviation; SNADA: sporadic nonampullary duodenal adenoma